


## HPK1-IN-21

Cat. No.:	HY-144073
CAS No.:	2413804-83-6
Molecular Formula:	C <sub>22</sub> H <sub>25</sub> ClFN <sub>5</sub> O <sub>2</sub>
Molecular Weight:	445.92
Target:	MAP4K
Pathway:	MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	HPK1-IN-21 is a potent inhibitor of HPK1 kinase inhibitor (Ki=0.8 nM). HPK1-IN-21 also has orally active <sup>[1]</sup> .												
<b>IC<sub>50</sub> &amp; Target</b>	HPK1 0.8 nM (Ki)												
<b>In Vitro</b>	HPK1-IN-21 (compound 25) (0.001, 0.01, 0.1, 1, 10, 100 μM; 4 hours) inhibits the activity of HPK1 kinase <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay <sup>[1]</sup>												
	Cell Line:	human pan T cells											
	Concentration:	0.001, 0.01, 0.1, 1, 10, 100 μM											
	Incubation Time:	4 hours											
	Result:	Resulted in the inhibition of HPK1 kinase activity											
<b>In Vivo</b>	HPK1-IN-21 (1, 25 mg/kg) shows 13% oral bioavailability in mouse when oral dose used 25 mg/kg <sup>[1]</sup> . Pharmacokinetic Parameters of HPK1-IN-21 in mice <sup>[1]</sup> .												
	<table border="1"> <thead> <tr> <th>compd</th> <th>LM H/R/M<sup>a,d</sup></th> <th>Hep H/R/M<sup>b,d</sup></th> <th>mouse iv CL,V<sub>ss</sub><sup>c</sup></th> <th>mouse F%<sup>c</sup></th> </tr> </thead> <tbody> <tr> <td>25</td> <td>6.9/8.7/38</td> <td>9.5/18/33</td> <td>57,1.9</td> <td>13%</td> </tr> </tbody> </table>	compd	LM H/R/M <sup>a,d</sup>	Hep H/R/M <sup>b,d</sup>	mouse iv CL,V <sub>ss</sub> <sup>c</sup>	mouse F% <sup>c</sup>	25	6.9/8.7/38	9.5/18/33	57,1.9	13%		
compd	LM H/R/M <sup>a,d</sup>	Hep H/R/M <sup>b,d</sup>	mouse iv CL,V <sub>ss</sub> <sup>c</sup>	mouse F% <sup>c</sup>									
25	6.9/8.7/38	9.5/18/33	57,1.9	13%									
<sup>a</sup> LM = Liver microsome predicted clearance (mL/min/kg), H = human, R = rat, M = mouse. <sup>b</sup> Hep = Hepatocyte clearance measured in mL/min/kg, H = human, R = rat, M = mouse. <sup>c</sup> Mouse PK: C57BL/6, 1 mg/kg iv dose or 25 mg/kg po dose, blood clearance measured in mL/min/kg, V <sub>ss</sub> = volume of distribution (L/kg). <sup>d</sup> HLM and Hep clearance values represent arithmetic means of two determinations. Six female (6-9 weeks) C57BL/6 mice, 15-25 g, 1 mg/kg iv (solution in 35% PEG400 in water); 25 mg/kg po (suspension in 0.5% methylcellulose, 0.2% Tween in water) <sup>[1]</sup> MCE has not independently confirmed the accuracy of these methods. They are for reference only.													

Animal Model:	Six female (6-9 weeks) C57BL/6 mice, 15-25 g <sup>[1]</sup>
Dosage:	1, 25 mg/kg
Administration:	
Result:	Showed 13% oral bioavailability in mice when oral dose used 25 mg/kg.

## REFERENCES

[1]. Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1). ACS Med Chem Lett. 2021, 13(1):84-91.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA